Skip to main content

sfRowasa Sulfite-Free Formulation

Generic: mesalamine

Data may be stale·Apr 23, 2026
Manufacturer
Meda
NDC
0037-0022
RxCUI
206798
Route
RECTAL
ICD-10 indication
K51.3

Affordability Check

How much will you actually pay for sfRowasa Sulfite-Free Formulation?

In 30 seconds, see every legitimate way to afford sfRowasa Sulfite-Free Formulation — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About sfRowasa Sulfite-Free Formulation

What is this medication? sfRowasa is a sulfite-free rectal suspension containing mesalamine, which belongs to a class of drugs known as aminosalicylates. This medication is specifically used to treat active mild to moderate distal ulcerative colitis, proctosigmoiditis, and proctitis. It works by delivering the active ingredient directly to the lining of the lower gastrointestinal tract to reduce inflammation and irritation in the colon and rectum.

The medication functions by inhibiting the production of certain chemicals in the body that cause redness and swelling in the digestive tract. This helps to alleviate common symptoms such as rectal bleeding, abdominal pain, and the urgent need for bowel movements. Because this version is sulfite-free, it provides a safer option for individuals who are allergic or sensitive to sulfite preservatives often found in other liquid medications.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How sfRowasa Sulfite-Free Formulation appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

0%

17 of 5,499 plans

Most common tier

Tier 4

On 67% of covering formularies

Prior authorization required

0%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)1
33%
Tier 4 (non-preferred brand)2
67%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 3 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.